Figure 1.

Model-derived percentages of physicians prescribing abiraterone or enzalutamide according to the magnitude of promotional payments received among A. medical oncologists and B. urologists

Source: Authors’ analysis of data from the Medicare Part D Event File, Open Payments Program, and Medicare Data on Physician Practice and Specialty.

Note: Percentages of physicians prescribing abiraterone or enzalutamide according to the magnitude of promotional payments received ($0 vs $1–$999 vs ≥$1000) were derived from three models: unadjusted (blue bar), adjusted (orange bar), and adjusted with exclusion of physicians prescribing abiraterone or enzalutamide in the 12 months prior to receiving their first promotional payment (gray bar). In the two adjusted models, year, physician age, physician gender, and region of practice were included as covariates. Across all three models, the percentages of physicians prescribing abiraterone or enzalutamide increased with higher payments for both specialties, with a notably steeper gradient of increase among urologists.